AGN: After Friday’s closing bell, Allergan (AGN 68.80, +0.52, +0.76%) reportedly received backing from a Food and Drug Administration advisory panel to make its weight-loss surgery device available to Americans with less-severe obesity.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.